<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">Researchers are working with different technologies, some of which have not previously been used in licensed vaccines. Six or more groups of volunteers have been injected with preparations; others have begun testing in animals (
 <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-020-01221-y" id="intref0050" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.nature.com/articles/d41586-020-01221-y</ext-link>).Research teams from different universities and companies around the world have produced more than 118 SARS-CoV-2 vaccines. The 18 candidate vaccines currently in clinical evaluation (
 <xref rid="tbl2" ref-type="table">Table 1</xref> ) (
 <xref rid="tbl2" ref-type="table">Table 2</xref> ) and 129 pre-clinical candidate vaccines included inactivated vaccines, recombinant subunit vaccines, 203 nucleic acid vaccines, adenovirus vector vaccines and recombinant influenza viruses 204 carrier vaccine (
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="intref0055" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link>).
</p>
